Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of R-MINE in relapsed or refractory diffuse large B-cell lymphoma
ChiCTR2200064503Phase 2Not yet recruiting
- Sponsor
- 37 Guoxue Alley, Wuhou District, Chengdu, Sichuan, China
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mitoxantrone-liposome, rituximab, ifosfamide, etoposide and mesna in diffuse large B-cell lymphoma (DLBCL), sponsored by 37 Guoxue Alley, Wuhou District, Chengdu, Sichuan, China. Primary endpoint: Overall response rate. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
mitoxantrone-liposomerituximabifosfamideetoposidemesna
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2200064503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064503.